APA-Zitierstil (7. Ausg.)

Hovinga, K. E., McCrea, H. J., Brennan, C., Huse, J. T., Zheng, J., Esquenazi, Y., . . . Tabar, V. (2019). EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.

Chicago-Zitierstil (17. Ausg.)

Hovinga, Koos E., Heather J. McCrea, Cameron Brennan, Jason T. Huse, Junting Zheng, Yoshua Esquenazi, Katherine S. Panageas, und Viviane Tabar. EGFR Amplification and Classical Subtype Are Associated with a Poor Response to Bevacizumab in Recurrent Glioblastoma. 2019.

MLA-Zitierstil (9. Ausg.)

Hovinga, Koos E., et al. EGFR Amplification and Classical Subtype Are Associated with a Poor Response to Bevacizumab in Recurrent Glioblastoma. 2019.